NLSP vs. CNTX, GRFS, LVTX, MYNZ, PHVS, PROC, QLI, TLSA, ATNFW, and SXTPW
Should you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include Context Therapeutics (CNTX), Grifols (GRFS), LAVA Therapeutics (LVTX), Mainz Biomed (MYNZ), Pharvaris (PHVS), Procaps Group (PROC), Qilian International Holding Group (QLI), Tiziana Life Sciences (TLSA), 180 Life Sciences (ATNFW), and 60 Degrees Pharmaceuticals (SXTPW). These companies are all part of the "medical" sector.
Context Therapeutics (NASDAQ:CNTX) and NLS Pharmaceutics (NASDAQ:NLSP) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, community ranking, media sentiment, valuation and risk.
Context Therapeutics has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of -0.83, suggesting that its stock price is 183% less volatile than the S&P 500.
Context Therapeutics received 2 more outperform votes than NLS Pharmaceutics when rated by MarketBeat users. Likewise, 58.82% of users gave Context Therapeutics an outperform vote while only 57.14% of users gave NLS Pharmaceutics an outperform vote.
Context Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 177.78%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Context Therapeutics is more favorable than NLS Pharmaceutics.
Context Therapeutics' return on equity of 0.00% beat NLS Pharmaceutics' return on equity.
14.0% of Context Therapeutics shares are held by institutional investors. 6.7% of Context Therapeutics shares are held by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Context Therapeutics had 2 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 3 mentions for Context Therapeutics and 1 mentions for NLS Pharmaceutics. Context Therapeutics' average media sentiment score of 0.50 beat NLS Pharmaceutics' score of -0.11 indicating that NLS Pharmaceutics is being referred to more favorably in the news media.
Summary
Context Therapeutics beats NLS Pharmaceutics on 8 of the 13 factors compared between the two stocks.
Get NLS Pharmaceutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NLSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NLS Pharmaceutics Competitors List
Related Companies and Tools
